Heart Failure vs Cardiomyopathy: Understanding the Distinction
Cardiomyopathy is a disease of the heart muscle itself, while heart failure is a clinical syndrome that can result from cardiomyopathy or many other cardiac conditions. 1
Core Definitions
Cardiomyopathy refers to heterogeneous myocardial disorders characterized by structural and functional abnormalities of the heart muscle that occur in the absence of coronary artery disease, hypertension, valvular disease, or congenital heart disease sufficient to explain the observed myocardial abnormality 1. Think of cardiomyopathy as the underlying disease process affecting the heart muscle.
Heart failure is a clinical syndrome characterized by elevated cardiac filling pressures (with or without reduced cardiac output) that manifests as signs and symptoms of congestion and potentially impaired perfusion 2, 3. Heart failure is the clinical consequence that can arise from multiple causes.
The Relationship: Cause vs Effect
The relationship works algorithmically:
- Cardiomyopathy → Heart Failure: Cardiomyopathy is one of many potential causes that can lead to heart failure 2, 4
- Heart Failure ≠ Cardiomyopathy: Heart failure can result from ischemic heart disease, hypertension, valvular disease, arrhythmias, or cardiomyopathies 2, 3
According to the 2022 AHA/ACC/HFSA guidelines, specific causes of heart failure include familial cardiomyopathy, infiltrative cardiac disease (amyloid, sarcoid, hemochromatosis), myocarditis, peripartum cardiomyopathy, stress cardiomyopathy, and substance abuse-related cardiomyopathy 2.
Classification Framework
Cardiomyopathies are classified by:
- Morphological phenotype: Dilated, hypertrophic, restrictive, arrhythmogenic right ventricular, or unclassified 1
- Etiology: Primary (genetic, nongenetic, acquired) or secondary (systemic diseases like amyloidosis, hemochromatosis, sarcoidosis) 1
Heart failure is classified by:
- Ejection fraction: HFrEF (reduced), HFmrEF (mid-range), HFpEF (preserved) 5
- Timing: Acute vs chronic
- Clinical presentation: Congestion and perfusion status 2
Critical Clinical Distinction
When evaluating a patient presenting with heart failure symptoms, the 2022 guidelines mandate that you obtain a thorough history and physical examination to identify the specific underlying cause, including whether a cardiomyopathy is present 2. This distinction matters because:
Disease-specific therapy exists: Certain cardiomyopathies (like cardiac amyloidosis) require targeted treatment beyond standard heart failure management 2
Genetic implications: If cardiomyopathy is identified, obtain a 3-generation family history to identify possible inherited disease, as this affects family screening and genetic counseling 2
Prognosis differs: Nonischemic cardiomyopathy generally has better prognosis than ischemic heart failure, and therapeutic responses to ACE inhibitors, beta-blockers, and other agents may differ 6
Common Pitfall to Avoid
Do not use "nonischemic cardiomyopathy" and "dilated cardiomyopathy" interchangeably. While often used synonymously in practice, this fails to recognize that nonischemic cardiomyopathy can include conditions caused by volume or pressure overload (hypertension, valvular disease) that don't meet the strict definition of dilated cardiomyopathy 1. Dilated cardiomyopathy specifically refers to ventricular dilation and depressed myocardial performance in the absence of hypertension, valvular, congenital, or ischemic heart disease 1.
Assessment Priorities
At each clinical encounter with heart failure patients, assess vital signs and evidence of clinical congestion (jugular venous distension, orthopnea, bendopnea, leg edema) to guide diuretic adjustment 2. Clinical congestion independently predicts quality of life and prognosis, even beyond natriuretic peptides 2.
For patients with identified cardiomyopathy, look for clinical clues suggesting advanced heart failure that may warrant referral to an advanced heart failure center for consideration of mechanical circulatory support or cardiac transplantation 2, 7.